<?xml version='1.0' encoding='utf-8'?>
<document id="18473508"><sentence text="[The role of anidulafungin therapy in solid organ transplant recipients]." /><sentence text="Anidulafungin is a new echinocandin recently approved for the treatment of esophageal candidiasis, candidemia and other forms of invasive candidiasis, such as peritonitis and intra-abdominal abscesses in non-neutropenic patients"><entity charOffset="0-13" id="DDI-PubMed.18473508.s2.e0" text="Anidulafungin" /><entity charOffset="23-35" id="DDI-PubMed.18473508.s2.e1" text="echinocandin" /><pair ddi="false" e1="DDI-PubMed.18473508.s2.e0" e2="DDI-PubMed.18473508.s2.e0" /><pair ddi="false" e1="DDI-PubMed.18473508.s2.e0" e2="DDI-PubMed.18473508.s2.e1" /></sentence><sentence text=" It is fungicidal against Candida spp" /><sentence text=" and fungistatic against Aspergillus spp" /><sentence text=" It is active against Pneumocystis jirovecii" /><sentence text=" In contrast, anidulafungin does not have activity against Cryptococcus neoformans, Zygomycetes or molds, other than Aspergillus spp"><entity charOffset="14-27" id="DDI-PubMed.18473508.s6.e0" text="anidulafungin" /></sentence><sentence text=" The drug is well tolerated, even in patients with renal or hepatic impairment" /><sentence text=" In contrast to other echinocandins, it does not significantly interfere with the cytochrome P450 pathway and has a low drug-drug interaction profile, including calcineurinic agents and other drugs used in transplant recipients"><entity charOffset="22-35" id="DDI-PubMed.18473508.s8.e0" text="echinocandins" /></sentence><sentence text=" So far, anidulafungin appears to have an excellent safety profile with few adverse events and it promises a special consideration in the management of fungal infections happening in transplant recipients" /><sentence text="" /></document>